JPWO2021142342A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021142342A5 JPWO2021142342A5 JP2022542340A JP2022542340A JPWO2021142342A5 JP WO2021142342 A5 JPWO2021142342 A5 JP WO2021142342A5 JP 2022542340 A JP2022542340 A JP 2022542340A JP 2022542340 A JP2022542340 A JP 2022542340A JP WO2021142342 A5 JPWO2021142342 A5 JP WO2021142342A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- improved
- seq
- protein
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062959685P | 2020-01-10 | 2020-01-10 | |
| US62/959,685 | 2020-01-10 | ||
| PCT/US2021/012804 WO2021142342A1 (en) | 2020-01-10 | 2021-01-08 | Compositions and methods for the targeting of pcsk9 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023510352A JP2023510352A (ja) | 2023-03-13 |
| JPWO2021142342A5 true JPWO2021142342A5 (https=) | 2024-01-16 |
| JP2023510352A5 JP2023510352A5 (https=) | 2024-01-16 |
Family
ID=74505368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022542340A Pending JP2023510352A (ja) | 2020-01-10 | 2021-01-08 | Ｐｃｓｋ９の標的化のための組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230167424A1 (https=) |
| EP (1) | EP4087930A1 (https=) |
| JP (1) | JP2023510352A (https=) |
| KR (1) | KR20220125332A (https=) |
| CN (1) | CN115427570A (https=) |
| AU (1) | AU2021206270A1 (https=) |
| CA (1) | CA3163714A1 (https=) |
| IL (1) | IL294620A (https=) |
| WO (1) | WO2021142342A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
| PH12021553076A1 (en) | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| AU2021392719B2 (en) | 2020-12-03 | 2025-08-14 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2022261150A2 (en) | 2021-06-09 | 2022-12-15 | Scribe Therapeutics Inc. | Particle delivery systems |
| US20250388885A1 (en) * | 2022-03-11 | 2025-12-25 | Epicrispr Biotechnologies, Inc. | Compositions, systems, and methods for treating familial hypercholesterolemia by targeting pcsk9 |
| WO2023235818A2 (en) * | 2022-06-02 | 2023-12-07 | Scribe Therapeutics Inc. | Engineered class 2 type v crispr systems |
| WO2023235888A2 (en) | 2022-06-03 | 2023-12-07 | Scribe Therapeutics Inc. | COMPOSITIONS AND METHODS FOR CpG DEPLETION |
| WO2023240027A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Particle delivery systems |
| WO2023240076A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| WO2023240074A1 (en) | 2022-06-07 | 2023-12-14 | Scribe Therapeutics Inc. | Compositions and methods for the targeting of pcsk9 |
| US20250361525A1 (en) | 2022-06-08 | 2025-11-27 | Scribe Therapeutics Inc. | Aav vectors for gene editing |
| IL317874A (en) | 2022-06-24 | 2025-02-01 | Tune Therapeutics Inc | Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression |
| JP2025532127A (ja) | 2022-09-23 | 2025-09-29 | アイオーニス ファーマシューティカルズ， インコーポレーテッド | Ｍｅｃｐ２発現を低減する化合物及び方法 |
| TW202444906A (zh) | 2023-03-29 | 2024-11-16 | 美商斯奎柏治療公司 | 用於靶向pcsk9之組合物及方法 |
| WO2024238723A1 (en) * | 2023-05-16 | 2024-11-21 | Omega Therapeutics, Inc. | Methods and compositions for modulating pcsk9 expression |
| CN118086311B (zh) * | 2023-05-25 | 2024-08-09 | 苏州时安生物技术有限公司 | 抑制PCSK9基因表达的siRNA、其缀合物和药物组合物及用途 |
| WO2025006782A2 (en) * | 2023-06-30 | 2025-01-02 | Chroma Medicine, Inc. | Guide rna compositions |
| CN116978457B (zh) * | 2023-09-22 | 2023-12-22 | 成都斯马特科技有限公司 | 避免rna检测过程中假基因干扰的引物和探针组合及其设计方法 |
| CN119506351B (zh) * | 2024-11-20 | 2025-08-19 | 中国人民解放军陆军军医大学第二附属医院 | 一体化pcsk9腺嘌呤碱基编辑系统及应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| WO2010075303A1 (en) | 2008-12-23 | 2010-07-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same |
| WO2012068627A1 (en) | 2010-11-24 | 2012-05-31 | The University Of Western Australia | Peptides for the specific binding of rna targets |
| CA2999649A1 (en) * | 2015-11-06 | 2017-05-11 | Crispr Therapeutics Ag | Materials and methods for treatment of glycogen storage disease type 1a |
| WO2017083722A1 (en) | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| CA3038960A1 (en) | 2016-09-30 | 2018-04-05 | The Regents Of The University Of California | Rna-guided nucleic acid modifying enzymes and methods of use thereof |
| EP3559223A1 (en) * | 2016-12-23 | 2019-10-30 | President and Fellows of Harvard College | Gene editing of pcsk9 |
| EP3585894A1 (en) * | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disorders |
| WO2018195555A1 (en) | 2017-04-21 | 2018-10-25 | The Board Of Trustees Of The Leland Stanford Junior University | Crispr/cas 9-mediated integration of polynucleotides by sequential homologous recombination of aav donor vectors |
| US11578334B2 (en) * | 2017-10-25 | 2023-02-14 | Monsanto Technology Llc | Targeted endonuclease activity of the RNA-guided endonuclease CasX in eukaryotes |
| WO2019126762A2 (en) * | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| PH12021553076A1 (en) * | 2019-06-07 | 2023-08-14 | Scribe Therapeutics Inc | Engineered casx systems |
| CA3153700A1 (en) * | 2019-09-09 | 2021-03-18 | Scribe Therapeutics Inc. | Compositions and methods for use in immunotherapy |
-
2021
- 2021-01-08 AU AU2021206270A patent/AU2021206270A1/en active Pending
- 2021-01-08 IL IL294620A patent/IL294620A/en unknown
- 2021-01-08 US US17/791,130 patent/US20230167424A1/en active Pending
- 2021-01-08 CN CN202180019446.7A patent/CN115427570A/zh active Pending
- 2021-01-08 EP EP21703125.1A patent/EP4087930A1/en active Pending
- 2021-01-08 KR KR1020227027481A patent/KR20220125332A/ko active Pending
- 2021-01-08 WO PCT/US2021/012804 patent/WO2021142342A1/en not_active Ceased
- 2021-01-08 CA CA3163714A patent/CA3163714A1/en active Pending
- 2021-01-08 JP JP2022542340A patent/JP2023510352A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021142342A5 (https=) | ||
| JP7493487B2 (ja) | 免疫を工学操作するための方法および組成物 | |
| US20230203540A1 (en) | Methods and compositions for nuclease-mediated targeted integration of transgenes into mammalian liver cells | |
| AU2017324462B2 (en) | Modulation of liver genes | |
| US9255250B2 (en) | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene | |
| EP3080143B1 (en) | Methods and compositions for treating hemophilia | |
| EP2890780B1 (en) | Methods and compositions for treatment of a genetic condition | |
| JP7832262B2 (ja) | 肝特異的ウイルスプロモーター及びその使用方法 | |
| AU2017379073B2 (en) | Compositions and methods for treating alpha-1 antitrypsin deficiency | |
| CN116836957A (zh) | 用于核酸酶介导的基因组工程改造的递送方法和组合物 | |
| Marsh et al. | Application of CRISPR-Cas9-mediated genome editing for the treatment of myotonic dystrophy type 1 | |
| CN118401658A (zh) | 调节pcsk9的方法及其用途 | |
| JP7756639B2 (ja) | Ｘ連鎖性若年網膜分離療法のためのｃｒｉｓｐｒおよびａａｖ戦略 | |
| JP2020527030A (ja) | 肝臓において目的のタンパク質を発現するためのプラットフォーム | |
| CA3147643A1 (en) | Compositions and methods for modulating hepatocyte nuclear factor 4-alpha (hnf4.alpha.) gene expression | |
| CN117230043B (zh) | Cas13蛋白及其应用 | |
| KR20250053925A (ko) | CRISPR-Cas13 시스템 및 이의 용도 | |
| CN113474454A (zh) | 可控的基因组编辑系统 | |
| JP2022548320A (ja) | アポリポタンパク質ｂ（ａｐｏｂ）遺伝子発現をモジュレートするための組成物および方法 | |
| CN114072518B (zh) | 用于治疗地中海贫血或镰状细胞病的方法和组合物 | |
| JP2025514304A (ja) | 遺伝子治療法のための組織特異的遺伝子外セーフハーバーの同定 | |
| WO2025261493A1 (zh) | 通过表观编辑靶向调节pcsk9的方法及其用途 | |
| HK40052425A (en) | Controllable genome editing system | |
| KR20260048590A (ko) | 유전자 편집 시스템 및 그 용도 | |
| HK40113388A (zh) | 调节pcsk9的方法及其用途 |